Navigation Links
Status of the E2007 (perampanel) Development Program
Date:4/10/2008

- Termination of Parkinson's Disease Clinical Development and Focus on

Neuropathic Pain and Epilepsy Indications -

TOKYO, April 11 /PRNewswire/ -- E2007 (perampanel) is a first-in-class, orally administered, highly selective non-competitive AMPA-type glutamate receptor antagonist, in development by Eisai for several indications, including Parkinson's disease, neuropathic pain, epilepsy, multiple sclerosis and migraine prophylaxis.

The AMPA receptor is widely present in almost all excitatory neuronal synapses. It is believed to play a role in a large number of central nervous system (CNS) diseases with different underlying pathophysiology, including neurodegenerative disorders, movement disorders, pain and psychiatric disorders. Eisai has been pursuing development of perampanel for several CNS indications, some of which are currently in Phase II and Phase III. The most advanced indication is Parkinson's disease for which Eisai has been conducting three global Phase III studies (Studies 301, 302 and 309) with perampanel as add-on therapy to levodopa in patients with late-stage disease. Additionally, Eisai is preparing for global Phase III studies for epilepsy and conducting two Phase II studies for neuropathic pain.

Following the completion of the first Phase III Study 301, we recently completed the second Phase III Study 302, which was primarily conducted in North America. Study 302 is a 20-week, double-blind, placebo-controlled study comparing two doses of 2mg and 4mg of perampanel to placebo. The results, compared with placebo, did not show a significant difference in the primary endpoint of reduction of "off" time (time when signs and symptoms of Parkinson's disease return as the effect of levodopa wears off). Perampanel was generally well tolerated. After analyzing the data, Eisai has decided to discontinue the Parkinson's disease program and not pursue regulatory submissions for this indication. Eisai will focus resou
'/>"/>

SOURCE Eisai Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
4. Marital Status Doesnt Affect Lung Cancer Survival
5. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
8. Chinese SFDA Grants Immtech Fast Track Status
9. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
10. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
11. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014   Zacks Equity Research ... Bull of the Day and Panera (Nasdaq: PNRA - Free ... Equity Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD - ... and Shire (Nasdaq: SHPG - Free Report ). ... Bull of the Day : The biotech ...
(Date:8/22/2014)... , August 22, 2014 ... Hospital TVs Today Lincor announced general availability ... Engagement solution that delivers a range of education, entertainment ...      (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , ... defining point of care patient engagement to bedside smart ...
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... Sept, 21 OmniComm Systems, Inc. (OTC ... of eClinical solutions and services announced that it will ... at the Hilton Beach Resort in Fort Lauderdale, Florida ... presentations and speakers from participating Life Science organizations. The ...
... The Pittsburgh Life Sciences Greenhouse (PLSG), the ... and business growth programs to western Pennsylvania,s life ... nationally recognized Executives-in-Residence (EIR) has launched a new ... (Ib2C(TM)). Ib2C(TM) Founder and CEO, Stephen ...
Cached Medicine Technology:OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 3Pittsburgh Life Sciences Greenhouse Executive-in-Residence Launches Medical Device Company 2Pittsburgh Life Sciences Greenhouse Executive-in-Residence Launches Medical Device Company 3Pittsburgh Life Sciences Greenhouse Executive-in-Residence Launches Medical Device Company 4
(Date:8/22/2014)... August 22, 2014 AWeber, one ... that currently helps more than 120,000 small businesses ... the attention of Shane Michaels, prompting an investigative review. ... element for any online marketing campaign, despite what some ... the marketing world,” reports Michaels. “AWeber is a great ...
(Date:8/22/2014)... MyWriters.com , an online source for ... for marketers to help them drive traffic to their ... Shane Michaels, prompting an investigative review. , “Anyone ... knows that content is king when it comes to ... even though content is extremely important, creating quality, original ...
(Date:8/22/2014)... This report studies the "Sample Preparation Market by ... Kits (Isolation, Purification), By Application (Genomics, Proteomics), by ... 2018" This market was valued at $4,254.8 million ... a CAGR of 5.9% from 2013 to 2018, ... 98 market data Tables and 23 Figures spread ...
(Date:8/22/2014)... Boston, Mass. (PRWEB) August 22, 2014 ... Chain Drug Stores (NACDS) Total Store Expo - which ... Boston Globe published a pro-pharmacy op-ed in its online ... medical care, enlist pharmacists ” is co-authored by Steven ... and Michael Malloy, PharmD, dean of the MCPHS University ...
(Date:8/22/2014)... Millennium Treatment Group has recently noticed an increase ... of drug use among teenagers. The treatment facility aims to ... work to minimize drug abuse. , America is currently seeing ... in history. According to the National Institute of Drug ... 12 or older—or 9.2 percent of the population—had used an ...
Breaking Medicine News(10 mins):Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 3Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2
... passed on a rare side effect of the smallpox vaccination he ... , The boy who is currently being treated at University of ... percent of his body. ,Eczema vaccinatum is an unusual ... receive the shot or their close contacts. , The ...
... journal Proceedings of the National Academy of Sciences. The report ... in// preventing tuberculosis, and scientists may do well to resurrect ... led by Dr. Roland Brosch of the Institut Pasteur ... vaccines used in immunization of 2 million children around ...
... the first in the state to perform a novel ... regeneration of the heart muscle after a// heart attack. ... in the country providing this new treatment modality as ... a privately funded cell-therapy company studying stem cells for ...
... gene variants in Hispanic women are linked to spontaneous preterm ... Washington University.// ,The research was presented at the ... 16. ,Preterm birth is a major cause of ... birth was suggested by racial disparity, a tendency to occur ...
... have developed a procedure that estimates the reproductive potential ... multiple births and to achieve a higher success rate ... fertilization procedures are performed each year in the United ... in IVF cycles, but only 34.3 percent resulted in ...
... part of the body, could be an indicator of common ... development of new treatment. ,Zinc had previously been ... brains of patients with Alzheimer's disease. It is also vital ... ,Zinc is particularly important for healthy skin and ...
Cached Medicine News:Health News:Toddler Infected With Rare Side Effect of Smallpox Vaccine 2Health News:TB Vaccines: Ring Out the New, Bring in the Old 2Health News:Vanderbilt Performs State's First Stem Cell Heart Regeneration Therapy 2Health News:Vanderbilt Performs State's First Stem Cell Heart Regeneration Therapy 3Health News:Gene Variants Linked to Preterm Birth in Hispanic Women 2
... M1 is an advanced desktop PC ... is a sophisticated 2 channel stimulation ... electrical stimulations, 2 sound stimulations and ... You can customize each stimulation independently. ...
... MagPro is the high performance magnetic stimulator for ... medical research. , ,MagPro is able to stimulate ... studies of the field/nerve interface can be done ... waveform and coil-current direction. , , , , ...
... The X-SIZER System is ... system for thrombus removal ... and saphenous vein grafts. ... steel cutter and,continuous evacuation. ...
... the perfect partner for growing your business ... scalable to meet your needs now and ... your Allura Xper FD20 system supports mixed-use ... to new technologies allows you to add ...
Medicine Products: